La Jolla Pharmaceutical Company (LJPC): Price and Financial Metrics


La Jolla Pharmaceutical Company (LJPC)

Today's Latest Price: $3.90 USD

0.07 (1.83%)

Updated Sep 25 4:00pm

Add LJPC to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

LJPC Stock Summary

  • La Jolla Pharmaceutical Co's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 6.41% of US listed stocks.
  • LJPC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 4.67% of US stocks.
  • As for revenue growth, note that LJPC's revenue has grown 48.45% over the past 12 months; that beats the revenue growth of 89.68% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to La Jolla Pharmaceutical Co, a group of peers worth examining would be FPRX, PZG, SLAB, GNTX, and MEIP.
  • LJPC's SEC filings can be seen here. And to visit La Jolla Pharmaceutical Co's official web site, go to lajollapharmaceutical.com.
LJPC Daily Price Range
LJPC 52-Week Price Range

LJPC Stock Price Chart Technical Analysis Charts


LJPC Price/Volume Stats

Current price $3.90 52-week high $9.71
Prev. close $3.83 52-week low $2.30
Day low $3.77 Volume 317,199
Day high $3.94 Avg. volume 791,449
50-day MA $4.10 Dividend yield N/A
200-day MA $5.41 Market Cap 106.71M

La Jolla Pharmaceutical Company (LJPC) Company Bio


La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. The company was founded in 1989 and is based in San Diego, California.


LJPC Latest News Stream


Event/Time News Detail
Loading, please wait...

LJPC Latest Social Stream


Loading social stream, please wait...

View Full LJPC Social Stream

Latest LJPC News From Around the Web

Below are the latest news stories about La Jolla Pharmaceutical Co that investors may wish to consider to help them evaluate LJPC as an investment opportunity.

Independent Director David Ramsay Just Bought A Handful Of Shares In La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Potential La Jolla Pharmaceutical Company (NASDAQ:LJPC) shareholders may wish to note that the Independent Director...

Yahoo | August 25, 2020

La Jolla Pharma +3.2% as director buys $187,000 worth

La Jolla Pharmaceutical (LJPC) is up 3.2% postmarket following disclosure that director David Ramsay bought 47,000 shares in a series of transactions over the past few days. The 25 transactions meant a total outlay of about $187,456. That makes up his entire direct beneficial ownership of the stock....

Seeking Alpha | August 24, 2020

La Jolla Pharmaceutical (NASDAQ:LJPC) Share Prices Have Dropped 87% In The Last Five Years

We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...

Yahoo | August 21, 2020

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress

SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and…

GlobeNewswire | August 6, 2020

Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company

SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive Officer. “Larry has an impressive track record bringing innovative treatments that address unmet medical needs to patients in the acute-care setting," said Kevin Tang, Chairman of La Jolla. “We are delighted to have Larry join the Company.”“I look forward to working with the La Jolla team to continue to expand patient access to GIAPREZA and XERAVA,” said Larry Edwards, President and Chief Executive Officer of La Jolla. “I am grateful to have the opportunity to join a company that focuses on improving outcomes in patients suffering from life-threatening diseases.” From 2015 to 2020, Mr...

Yahoo | July 28, 2020

Read More 'LJPC' Stories Here

LJPC Price Returns

1-mo -4.65%
3-mo -11.16%
6-mo -7.14%
1-year -57.65%
3-year -88.65%
5-year -84.85%
YTD -0.76%
2019 -58.32%
2018 -70.70%
2017 83.57%
2016 -35.07%
2015 46.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8396 seconds.